Hofmeyer Kimberly A, Bianchi Katherine M, Wolfe Daniel N
US Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, Washington, DC 20201, USA.
Vaccines (Basel). 2022 Mar 12;10(3):436. doi: 10.3390/vaccines10030436.
As the global response to COVID-19 continues, government stakeholders and private partners must keep an eye on the future for the next emerging viral threat with pandemic potential. Many of the virus families considered to be among these threats currently cause sporadic outbreaks of unpredictable size and timing. This represents a major challenge in terms of both obtaining sufficient funding to develop vaccines, and the ability to evaluate clinical efficacy in the field. However, this also presents an opportunity in which vaccines, along with robust diagnostics and contact tracing, can be utilized to respond to outbreaks as they occur, and limit the potential for further spread of the disease in question. While mRNA-based vaccines have proven, during the COVID-19 response, to be an effective and safe solution in terms of providing a rapid response to vaccine development, virus vector-based vaccines represent a class of vaccines that can offer key advantages in certain performance characteristics with regard to viruses of pandemic potential. Here, we will discuss some of the key pros and cons of viral vector vaccines in the context of preparing for future pandemics.
随着全球对新冠疫情的应对持续进行,政府利益相关者和私人合作伙伴必须关注未来可能引发大流行的下一个新兴病毒威胁。目前被视为这些威胁之一的许多病毒家族,目前会引发规模和时间难以预测的散发性疫情。这在获取足够资金来研发疫苗以及在实地评估临床疗效的能力方面都构成了重大挑战。然而,这也带来了一个机会,即疫苗以及强大的诊断和接触者追踪手段可用于应对疫情的发生,并限制相关疾病进一步传播的可能性。虽然基于信使核糖核酸的疫苗在应对新冠疫情期间已证明是一种有效且安全的解决方案,能够对疫苗研发做出快速响应,但基于病毒载体的疫苗是一类在应对具有大流行潜力的病毒时,在某些性能特征方面可提供关键优势的疫苗。在此,我们将在为未来大流行做准备的背景下,讨论病毒载体疫苗的一些关键优缺点。